InvestSMART

Paradigm Biopharmaceuticals Limited (ASX: PAR) - Announcements

- Current share price for PAR : $0.245

ASX company news and announcements for Paradigm Biopharmaceuticals Limited (PAR) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Paradigm Biopharmaceuticals Limited (PAR) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Paradigm Biopharmaceuticals Limited (PAR), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Paradigm Biopharmaceuticals Limited (PAR)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$153 Appendix 4D and Half Year Report 28 Feb 2025 8:12AM $0.540 $0.245 fallen by 54.63%
$153 Paradigm Secures Ethics Approval for Phase 3 Trial 24 Feb 2025 8:06AM $0.615 $0.245 fallen by 60.16%
$153 Change of Director's Interest Notice 14 Feb 2025 2:41PM $0.513 $0.245 fallen by 52.20%
$153 Change of Director's Interest Notice 14 Feb 2025 2:41PM $0.513 $0.245 fallen by 52.20%
$153 Listing of Options - Top 20 Holders and Distribution Reports 11 Feb 2025 9:10AM $0.540 $0.245 fallen by 54.63%
$153 Application for quotation of securities - PAR 11 Feb 2025 9:02AM $0.540 $0.245 fallen by 54.63%
$153 Proposed issue of securities - PAR 3 Feb 2025 8:28AM $0.585 $0.245 fallen by 58.12%
$153 Cancel - Proposed issue of securities - PAR 3 Feb 2025 8:28AM $0.585 $0.245 fallen by 58.12%
$153 Proposed issue of securities - PAR 31 Jan 2025 4:29PM $0.585 $0.245 fallen by 58.12%
$153 Loyalty and Piggyback Options Program 31 Jan 2025 3:39PM $0.570 $0.245 fallen by 57.02%
$153 PAR Selects Advanced Clinical as CRO for Phase 3 31 Jan 2025 8:19AM $0.555 $0.245 fallen by 55.86%
$153 Quarterly Activities/Appendix 4C Cash Flow Report 30 Jan 2025 3:28PM $0.560 $0.245 fallen by 56.25%
$153 Application for quotation of securities - PAR 29 Jan 2025 6:37PM $0.540 $0.245 fallen by 54.63%
$153 Paradigm Receives $6.3m R&D Tax Refund 24 Jan 2025 8:59AM $0.440 $0.245 fallen by 44.32%
$153 Notice of release of escrowed securities 16 Jan 2025 4:22PM $0.435 $0.245 fallen by 43.68%
$153 Change of Director's Interest Notice 30 Dec 2024 12:05PM $0.380 $0.245 fallen by 35.53%
$153 Notification regarding unquoted securities - PAR 20 Dec 2024 3:25PM $0.380 $0.245 fallen by 35.53%
$153 Cleansing Notice 13 Dec 2024 8:29AM $0.420 $0.245 fallen by 41.67%
$153 Application for quotation of securities - PAR 13 Dec 2024 8:24AM $0.420 $0.245 fallen by 41.67%
$153 PAR Capital Raising Presentation 9 Dec 2024 9:24AM $0.580 $0.245 fallen by 57.76%
$153 Proposed issue of securities - PAR 9 Dec 2024 9:21AM $0.580 $0.245 fallen by 57.76%
$153 Successful Completion of $16M Placement for Phase 3 9 Dec 2024 9:21AM $0.580 $0.245 fallen by 57.76%
$153 Change of Director's Interest Notice 5 Dec 2024 5:25PM $0.580 $0.245 fallen by 57.76%
$153 Change of Director's Interest Notice 5 Dec 2024 5:12PM $0.580 $0.245 fallen by 57.76%
$153 Trading Halt 5 Dec 2024 8:45AM $0.580 $0.245 fallen by 57.76%

126 - 150 of 733 results

Page 6 of 30

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.